GRI Bio, Inc.【GRI】

時価総額

$22.9万

PER

免疫応答異常に伴う炎症・線維化疾患向け治療の新興企業。NKT細胞標的の主力候補GRI-0621を開発。2022年12月の主要投資家による1万2250ドル出資、2023年4月の合併を実施。米国ラホヤ拠点で臨床開発を展開。

	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-9	-7	-13	-8
Depreciation	-	-	0	0
Amortization of debt discounts and issuance costs	-	-	2	-
Stock-based compensation expense	1	0	0	0
Fair Value Adjustment of Warrants	-	-0	-0	-0
Change in operating lease right of use assets	-	-	0	-
Change in operating lease right of use assets	-	-	-	0
Prepaid expenses and other current assets	0	-0	1	-0
Accounts payable	-0	-0	2	-0
Accrued expenses	1	-1	0	-0
Operating lease liabilities	-	-	-0	0
Cash used in operating activities	-8	-7	-9	-9
Purchase of property and equipment	-	-	0	-
Cash used in investing activities	-4	4	-0	-
Advances from employees	-	-	0	-
Repayment of advances from employees	-	-	0	-
Proceeds from Notes Payable	-	-	1	-
Through Financing	-	-	-	9
At The Market Offering	-	-	-	4
Proceeds from issuance of common stock in financing transaction / under ATM facility	-	-	12	-
Proceeds from warrant exercise	-	-	0	1
Payment for fractional shares in connection with reverse stock split	-	-	-	0
Cash acquired in reverse recapitalization	-	-	1	-
Payment of reverse recapitalization costs	-	-	3	-
Payment of deferred stock issuance costs	-	-	1	2
Payment of debt issuance costs	-	-	0	-
Cash provided by financing activities	16	3	11	12
Net increase in cash and cash equivalents	4	0	2	3
Stock Issued For Repayment Of Notes Payable	-	-	3	-
Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants	-	-	1	-
Net Liabilities Assumed In Connection With Reverse Recapitalization	-	-	4	-
Debt Issuance Costs and Financing Costs Incurred But Not Yet Paid	-	-	0	-
Stock Issued For Payment Of Reverse Recapitalization Costs	-	-	2	-
Warrants Issued	-	-	0	0